Day: May 16, 2022

– Strong execution across atai’s three strategic pillars: rapid acting pharmacological intervention, ongoing digital support and biomarker-driven precision mental health – Key milestones include first subject dosed in Phase 1 KUR-101, launch of drug discovery engine Invyxis, initiation of Psyber usability study in patients and COMPASS’ end of Phase 2 FDA meeting – Ended the first quarter with $335 million cash, maintaining atai’s position as a well-funded, leading mental health company Video interview with Management to be posted today at 8:30 a.m. EDT NEW YORK and BERLIN, May 16, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today reported financial results for the quarter ended March 31, 2022 and...

Company announcement 9/2022 (16.05.2022) European Energy saw progress in both power and asset sales in Central and South Europe making the basis for a record quarter. The EBITDA for the company reached EUR 65 million and profit before tax EUR 63 million. Progress in both power and asset sales in Central and South Europe ensured a record quarter for European Energy with an EBITDA of EUR 65 million and profit before tax of EUR 63 million. The strong numbers originate from power sale and divestment of projects mainly in central and south Europe. The power sale reached the highest level in Q1 and contributed EUR 26 million in the first quarter of 2022. That is an increase of 144% compared to Q1 in 2021 (EUR 11 million). In total, European Energy sold more than 229 GWh of renewable energy in Q1 2022 which is an increase of more than 50 percent...

Announced U.S. co-development and co-commercialization agreement for CLN-081 with Taiho Pharmaceutical; updated CLN-081 data accepted for oral presentation at the American Society for Clinical Oncology (ASCO) meeting in June CLN-049 and CLN-619 Phase I dosing continues with initial clinical data on track for mid-2023; CLN-081 and CLN-978 IND submissions on track for 1H 2023 Cash of $685 million1, including upfront payment for the Taiho collaboration, provides expected runway through 2026. CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today reported on recent and upcoming business highlights and announced its financial results for the first quarter ended March 31, 2022. “We...

HOUSTON, May 16, 2022 (GLOBE NEWSWIRE) — Vantage Drilling International (“Vantage” or the “Company”) reported a net loss attributable to controlling interest of approximately $14.9 million, or $1.14 per diluted share, for the three months ended March 31, 2022, based on the weighted average shares outstanding, as compared to a net loss attributable to controlling interest of $36.0 million, or $2.74 per diluted share, for the three months ended March 31, 2021. As of March 31, 2022, Vantage had approximately $78.6 million in cash, including $16.4 million of restricted cash, compared to $90.6 million in cash, including $17.3 million of restricted cash, at December 31, 2021. The Company used $8.2 million in cash from operations during the first quarter of 2022 compared to $15.4 million used during the same period of 2021. Ihab...

Clinical trial sites open and enrolling patients in FDA and EMA registration-directed Phase III Part A study of nomacopan in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) FDA and EMA registration-directed Phase III Part A study of nomacopan in bullous pemphigoid (BP) is open for enrollment Advanced the development of long-acting PAS-nomacopan for geographic atrophy/dry age-related macular degeneration (GA/dAMD); preclinical data showed PAS-nomacopan effective in the inhibition of choroidal neovascularization (CNV) and suggested a clinical dose interval of three months may be possible   Increased the total manufacturing yield of investigational nomacopan more than five-fold Appointment of industry veteran Rachelle Jacques as President and CEONEW YORK and LONDON, May 16, 2022 (GLOBE NEWSWIRE)...

SEATTLE and CAMBRIDGE, United Kingdom, May 16, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended March 31, 2022. “We are excited about the potential of our pipeline in multiple neuronal excitability disorders,” said Bob Azelby, president and chief executive officer of Eliem Therapeutics. “While disappointed by the negative outcome of ETX-810 in diabetic peripheral neuropathic pain, we look forward to providing the topline Phase 2a data for ETX-810 in lumbosacral radicular pain, the chronic pain...